Ilmarinen Mutual Pension Insurance Co Has $4.89 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Ilmarinen Mutual Pension Insurance Co boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 40.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,000 shares of the medical research company’s stock after acquiring an additional 19,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Edwards Lifesciences were worth $4,886,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $610,895,000. Jennison Associates LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $555,939,000. Vanguard Group Inc. grew its holdings in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $213,844,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,153,526.69. This trade represents a 27.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock worth $4,513,064 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on EW shares. Citigroup raised their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Down 4.9 %

Shares of EW stock opened at $69.39 on Friday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a 50-day simple moving average of $71.74 and a two-hundred day simple moving average of $70.64. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $40.79 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.